Please login to the form below

The fight against COVID-19 needs to have diversity at the heart of its strategy

There are too many conditions and diseases that have treatments and medicines developed without true testing on the minority populations they affect most. So for too many people, they simply don’t work. If we’re going to stand by the mantra that “we’re all in this together” shouldn’t we be putting it into action in every way we can?

Firstly, we must start by saying that we recognise that the journey from we when first understood COVID-19 to be a global pandemic, to where we are now, has been a whirlwind. It’s not something we were prepared for (despite previous virus outbreaks – we’re only human eh?), and we’re all learning as we go. That said, we can’t look at the efforts being made through rose-tinted glasses. Yes, we need to unite, be supportive and help not hinder. But in order to uncover truths and to really do our best by all humankind, we have to highlight where we’re going wrong, too. And one of those not so great areas that we’re all too aware of at COUCH Health, is how the tracking and reporting of coronavirus victims is overlooking clear ethnic and cultural differences.

Look closer at the victims

It’s important to note that coronavirus can affect anyone. However, take a closer look at the data that are currently available, and there’s plenty of reason to believe that some communities are more affected than others. For example:

  • 70% of reported coronavirus victims in Chicago were black, despite representing only 30% of the population.
  • 70% of reported deaths in Louisiana are black people, who make up 32% of the population.
  • 40% of deaths reported in Michigan are black people, yet they make only 15% of the population.

The UK is yet to provide any breakdown of victim data by ethnicity, but there’s evidence that tells a similar story from the Intensive Care National Audit and Research Centre, based on 3,300 patients from intensive care units across England, Wales and Northern Ireland. It suggests that 34% of critically ill coronavirus patients are from black or minority ethnic backgrounds, which is more than double the representation in the wider population.

Frontline fatalities

Something that should have really stood out to everyone keeping up with the news in the UK, is that the first four doctors to lose their lives treating COVID-19 patients were men of African or Asian heritage. And their deaths were followed by a black healthcare assistant and a nurse of Pakistani decent.

On a first look, it tells a shocking story, right? But understanding that one in five people working for the NHS in England are from an ethnic minority background (a number that increases when you just take into consideration doctors and nurses) does give some context. Ethnic minority staff make up 40% of the NHS’s workforce, which is more than double their proportion in the UK population.

Context aside, there’s no denying that ethnic minorities are being impacted in a higher proportion. In recognition of this, the #CharitySoWhite campaign has demanded action over the disproportionate impact of the virus on Britain’s minorities. Their report goes further than just looking at key workers, and reveals evidence that reduced access to health treatment compared with white people, the impact of school closures, lower income and insecure housing put ethnic minorities at greater risk. That action they’re demanding from their campaign needs to come from all key decision makers involved, including those in the clinical research world…

A time for change in clinical trials

As we said at the start, action has been taken at a faster pace than normal when making decisions around responses to the COVID-19 pandemic. But when it comes to clinical research, producing valid scientific results that are inclusive of all whom the virus can affect is vital and can’t be an afterthought.

There’s clear evidence that all ethnicities can be affected by coronavirus, and that ethnic minorities in particular are impacted most. So, clinical trials looking to develop vaccines and medicines that actually work need to be trialling them on those who are most vulnerable to contracting the virus. There’s simply no excuse to fail to fairly represent members of minority populations in clinical studies. Overlooking this will mean that there’s yet another condition where treatment is less available and less effective to these populations.

Right now, not enough is being done to track infections by ethnic groups. If we don’t truly understand who, then how can we even begin to speak to the right people needed to take part in a clinical trial? How are we supposed to create treatments, guidance, and interventions that will actually make a real difference to those who the virus impacts most?

The simple answer is that we can’t, so we won’t. And where does that leave us in our fight against this global pandemic? We’d say, defeated.

There are too many conditions and diseases that have treatments and medicines developed without true testing on the minority populations they affect most. So for too many people, they simply don’t work. If we’re going to stand by the mantra that “we’re all in this together” shouldn’t we be putting it into action in every way we can? Shouldn’t the clinical research industry be leading the way if we’re going to be leading the fight against the virus? We think so, here at COUCH Health. What do you think?

This blog was originally published here.

17th April 2020

Share

Tags

Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Address:
Suite 2.10, Jactin House
24 Hood Street
Manchester
M4 6WX
United Kingdom

Latest content on this profile

Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same. So, let’s quickly clear up once and for all what the difference between patient engagement and patient experience is, so we can make sure that we’re doing the best possible job in both areas…
COUCH Health
Building trust in clinical trials whilst it is in the public eye
We’re all well aware that healthcare organisations are generally perceived to be untrustworthy. According to Edelman’s 2018 Trust Barometer, we even saw a clear global decline of public trust in pharma, biotech, hospitals, insurance and consumer health companies.
COUCH Health
Diversity in clinical trials needs to extend beyond COVID-19 vaccine trails
First up, the hard truth is that clinical trial populations are not diverse. People of certain ethnicities, females and the elderly are typically underrepresented in clinical research. And you might ask, “why?”
COUCH Health
Insights from patients during the COVID-19 pandemic
We all know how much the COVID-19 pandemic has affected everyone around the world. And within the healthcare industry, priorities have been re-evaluated and processes changed, to ensure that patients keep receiving care.
COUCH Health
September 2020: diversity and inclusion in clinical trials round-up
Our latest round-up takes a closer look at the different conditions where health disparities are present, such as more women living with multiple sclerosis (MS), and the cancer death rate being highest among Black people vs all other ethnic groups. Plus, there are a couple of articles with important insights about inequalities in LGBTQ+ communities, too.
COUCH Health
Why Facebook is not the solution to inclusive patient recruitment
With so many clinical trials underway to find an effective vaccine for COVID-19, the competition is rising. More and more organisations will be looking to recruit healthy volunteers, while ensuring inclusion and diversity in clinical trials, to complete their mission of finding a vaccine and making it available to the public as quickly as possible.
COUCH Health